ALA got just the iNKT - licence which is co-developed with IMU at pre-clinical stage, not more cash than CHM and yet is valued at $40m and rising while CHM is valued about 10-12m.
If ALA is fairly valued, how high should the CHM sp be? Based on the clinical trials, 20-30c.
What is Mr Market doing?
GLTA
CHM Price at posting:
3.9¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)